Physician profile
Donald A Garrow
NPI 1215045182
$45,187.10
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $4,813.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $44,115.98 | 2019-2020 | |
| Cook Medical LLC | $374.66 | 2019 | |
| Allergan, INC. | $157.58 | 2019-2020 | |
| Pfizer INC. | $125.74 | 2019 | |
| Ironwood Pharmaceuticals, INC | $96.45 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.22 | 2019-2020 | |
| Janssen Biotech, INC. | $55.56 | 2020 | |
| Gilead Sciences, INC. | $47.59 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.88 | 2019-2020 | |
| Boston Scientific Corporation | $33.18 | 2019 | |
| Ucb, INC. | $31.15 | 2019 | |
| Shionogi INC | $20.98 | 2019 | |
| Vivus LLC | $14.13 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Garrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.